ESMO 2023 | JCOG1611: nab-paclitaxel/gemcitabine vs. FOLFIRINOX/S-IROX in met or recurrent pancreatic cancer

Akihiro Ohba, MD, National Cancer Centre, Tokyo, Japan, discusses a Phase II/III JCOG1611-GENERATE (jRCTs031190009) trial comparing first-line treatments for metastatic pancreatic cancer. The study, conducted in 45 centers in Japan, compared nab-paclitaxel plus gemcitabine, modified FOLFIRINOX, and S-IROX. Enrolling 527 patients, the trial was terminated for futility at the planned interim analysis in March 2023. Nab-paclitaxel plus gemcitabine demonstrated superior median overall survival (17.1 months) compared to modified FOLFIRINOX (14.0 months) and S-IROX (13.6 months). Notably, the most common grade 3–4 non-hematological toxicity of anorexia was higher in the FOLFIRINOX and S-IROX arms. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.